The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients - European Medical Journal

The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some of the difficulties with using Ki-67, a nuclear protein associated with cellular proliferation, as a predictive parameter for response to adjuvant chemotherapy in breast cancer patients.

This content is supported by Genomic Health, Inc.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now